(Q34669232)

3 August 2017

1 reference

title

Review article: the management of refractory Crohn's disease (English)

1 reference

3 August 2017

0 references

Rizzello F

1

1 reference

3 August 2017

Gionchetti P

2

1 reference

3 August 2017

Venturi A

3

1 reference

3 August 2017

Morselli C

4

1 reference

3 August 2017

Campieri M

5

1 reference

3 August 2017

language of work or name

English

0 references

publication date

1 July 2002

1 reference

Alimentary Pharmacology & Therapeutics

3 August 2017

published in

1 reference

3 August 2017

volume

16 Suppl 4

1 reference

3 August 2017

page(s)

40-47

1 reference

Clinical, biological, and endoscopic picture of attacks of Crohn's disease. Evolution on prednisolone. Groupe d'Etude Thérapeutique des Affections Inflammatoires Digestives.

3 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.16.S4.6.X

Clinical aspects of glucocorticoid sensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.16.S4.6.X

The mechanism for glucocorticoid-resistance in a rat hepatoma cell variant that contains functional glucocorticoid receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.16.S4.6.X

Glucocorticoid receptors are down-regulated in inflamed colonic mucosa but not in peripheral blood mononuclear cells from patients with inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.16.S4.6.X

Review article: the limitations of corticosteroid therapy in Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.16.S4.6.X

Pharmacogenetics of acute azathioprine toxicity: relationship to thiopurine methyltransferase genetic polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.16.S4.6.X

Sulphasalazine inhibition of thiopurine methyltransferase: possible mechanism for interaction with 6-mercaptopurine and azathioprine

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.16.S4.6.X

Leucopenia resulting from a drug interaction between azathioprine or 6-mercaptopurine and mesalamine, sulphasalazine, or balsalazide

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.16.S4.6.X

Risk of lymphoma in inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.16.S4.6.X

A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.16.S4.6.X

A nonsecretable cell surface mutant of tumor necrosis factor (TNF) kills by cell-to-cell contact

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.16.S4.6.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.16.S4.6.X

A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.16.S4.6.X

Methotrexate for the Treatment of Crohn's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.16.S4.6.X

Assay of 6-thioinosinic acid and 6-thioguanine nucleotides, active metabolites of 6-mercaptopurine, in human red blood cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.16.S4.6.X

Enhanced bioavailability of azathioprine compared to 6-mercaptopurine therapy in inflammatory bowel disease: correlation with treatment efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.16.S4.6.X

6-Mercaptopurine in the management of inflammatory bowel disease: short- and long-term toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.16.S4.6.X

Crohn's disease and cancer: a population-based cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.16.S4.6.X

Tumour necrosis factor alpha in stool as a marker of intestinal inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.16.S4.6.X

Tumor necrosis factor alpha-producing cells in the intestinal mucosa of children with inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.16.S4.6.X

Tumour-necrosis-factor antibody treatment in Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.16.S4.6.X

Infliximab in Crohn's disease: first anniversary clinical experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.16.S4.6.X

Mechanisms in failure of infliximab for Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.16.S4.6.X

Endoscopic monitoring of Crohn's disease treatment: a prospective, randomized clinical trial. The Groupe d'Etudes Therapeutiques des Affections Inflammatoires Digestives

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.16.S4.6.X

Infliximab induces potent anti-inflammatory and local immunomodulatory activity but no systemic immune suppression in patients with Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.16.S4.6.X

10.1046/J.1365-2036.16.S4.6.X

21 January 2018

Identifiers

DOI

1 reference

3 August 2017

1 reference